A Phase I Study Of Two Administration Schedules Of The Polo-Like Kinase 1 Inhibitor Bi 2536 In Patients With Advanced Solid Tumors.

G. Munzert,S. Steinbild,A. Frost, S. Hedborn, J. Rentschler, R. Kaiser,D. Trommeshauser, M. Hoffmann,M. Steegmaier, K. Mross

JOURNAL OF CLINICAL ONCOLOGY（2006）

引用 10|浏览2

暂无评分

摘要

3069 Background: BI 2536 is a novel highly potent and selective inhibitor of the serine-threonine Polo-like kinase 1 (Plk1), a key regulator of cell cycle progression. Objectives of this trial were...

查看译文

关键词

inhibitor inhibitor,advanced solid tumors,polo-like

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要